中华皮肤科杂志 ›› 2023, e20210875.doi: 10.35541/cjd.20210875

• 综述 • 上一篇    下一篇

本维莫德在皮肤病中的研究进展

陈良宏1,2    孙艳1    王敬玉   吴严1   

  1. 1中国医科大学附属第一医院皮肤科,沈阳  110001;2中国医科大学附属盛京医院急诊科,沈阳  110801
  • 收稿日期:2021-12-02 修回日期:2022-03-21 发布日期:2023-03-20
  • 通讯作者: 吴严 E-mail:jlwuyan@126.com
  • 基金资助:
    国家自然科学基金(82103758)

Benvitimod for the treatment of dermatoses

Chen Lianghong1,2, Sun Yan1, Wang Jingyu1, Wu Yan1   

  1. 1Department of Dermatology, The First Hospital of China Medical University, Shenyang 110001, China; 2Department of Emergency Medicine, Shengjing Hospital of China Medical University, Shenyang 110801, China
  • Received:2021-12-02 Revised:2022-03-21 Published:2023-03-20
  • Contact: Wu Yan E-mail:jlwuyan@126.com
  • Supported by:
    National Natural Science Foundation of China(82103758)

摘要: 【摘要】 本维莫德是一种芳香烃受体激动剂,通过不同途径抑制各种炎症因子的表达,对银屑病、特应性皮炎、白癜风、接触性皮炎及玫瑰痤疮等炎症性皮肤病起到一定的治疗作用。本文总结分析本维莫德在皮肤病中的研究进展,以期加深对本维莫德生物效应的认识。

关键词: 受体, 芳香烃, 皮肤疾病, 银屑病, 皮炎, 特应性, 红斑痤疮, 本维莫德

Abstract: 【Abstract】 Benvitimod is an aryl hydrocarbon receptor agonist, and has a certain therapeutic effect on some inflammatory dermatoses, such as psoriasis, atopic dermatitis, vitiligo, contact dermatitis and rosacea, by inhibiting the expression of various inflammatory factors via different pathways. This review focuses on research progress in benvitimod for the treatment of dermatoses, with a view to deepening the understanding of its biological effects.

Key words: Receptors, aryl hydrocarbon, Skin disease, Psoriasis, Dermatitis, atopic, Rosacea, Benvitimod

引用本文

陈良宏 孙艳 王敬玉 吴严. 本维莫德在皮肤病中的研究进展[J]. 中华皮肤科杂志, 2023,e20210875. doi:10.35541/cjd.20210875

Chen Lianghong, Sun Yan, Wang Jingyu, Wu Yan. Benvitimod for the treatment of dermatoses[J]. Chinese Journal of Dermatology,2023,e20210875. doi:10.35541/cjd.20210875